An official website of the United States government

Citation
Magee, John (2024). Longitudinal Study of Genetic Causes of Intrahepatic Cholestasis (LOGIC) (Version 5) [Dataset] NIDDK Central Repository. https://doi.org/10.58020/dbbh-rt92
Data Availability Statement
Data from the Longitudinal Study of Genetic Causes of Intrahepatic Cholestasis (LOGIC) [(Version 5) https://doi.org/10.58020/dbbh-rt92] reported here are available for request at the NIDDK Central Repository (NIDDK-CR) website, Resources for Research (R4R), https://repository.niddk.nih.gov/.
Acknowledgment Statement
The LOGIC study was conducted by the study investigators and supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The resources from the LOGIC (https://doi.org/10.58020/dbbh-rt92) study reported here were supplied by NIDDK Central Repository (NIDDK-CR) and are available for request at https://repository.niddk.nih.gov. This manuscript was not prepared under the auspices of the LOGIC study and does not necessarily reflect the opinions or views of the LOGIC study, NIDDK-CR, or NIDDK.
Resource Availability
Specimens and Study Datasets
Publications
Explore publications resulting from the use of study resource
View publications (2)

General Description

Cholestasis, a rare condition involving a reduction or obstruction of bile flow from the liver to the small intestine, can cause significant growth problems, liver complications, the need for liver transplantation, and death. The four rare genetic disorders Alagille syndrome (ALGS), alpha-1 antitrypsin (a-1AT) deficiency, bile acid synthesis defects, and progressive familial intrahepatic cholestasis (PFIC) account for approximately 20% to 30% of all infant cases of cholestasis. Current knowledge concerning the etiology and outcomes of these diseases is limited. The Longitudinal Study of Genetic Causes of Intrahepatic Cholestasis (LOGIC) study is a longitudinal cohort study that was established by the Childhood Liver Disease Research and Education Network (ChiLDReN) to investigate the natural history and progression of these four genetic disorders.

Children and adults ages 6 months through 25 years who have been diagnosed with ALGS, a-1AT deficiency, bile acid synthesis defects, and PFIC are enrolled. Individuals who are siblings of a-A1T participants and have underlying disease with no evidence of liver involvement may also be enrolled. Participants will complete a baseline visit and give annual follow-up visits. Study visits involve review of clinical information, family history, and any treatments and their outcomes. A physical exam, laboratory tests, and radiologic and imaging evaluations will also be performed. In addition to these standard of care evaluations, participants will undergo neurodevelopment evaluations, DEXA scanning, hearing exams, and liver histology studies. The primary outcome measure is the evaluation of disease progression for each condition, which includes assessment of growth failure, worsening liver functions, developmental complications of portal high blood pressure, liver transplantation, and death. Jaundice, listing for liver transplantation, calculated pediatric end-stage liver disease (PELD) score or model for end-stage liver disease (MELD) score, health-related quality of life, growth, bone mineral density, and presence of hearing loss are assessed as secondary outcome measures.

The data package now includes analysis datasets from multiple publications.

Objectives

The primary objectives of the LOGIC study include determining the frequency of poor growth and decreased bone mineral density and its predictors; identifying modifier genes that influence the incidence, severity, and progression of liver disease among affected individuals; and developing a repository of biospecimens to be used in ancillary studies of predictor biomarkers.

Outcome Measure

The primary outcome measure is the evaluation of disease progression for each condition, which includes assessment of growth failure, worsening liver functions, developmental complications of portal high blood pressure, liver transplantation, and death. Jaundice, listing for liver transplantation, calculated pediatric end-stage liver disease (PELD) score or model for end-stage liver disease (MELD) score, health-related quality of life, growth, bone mineral density, and presence of hearing loss are assessed as secondary outcome measures.

Eligibility Criteria

Children and young adults between the ages of 6 months and 25 years who are diagnosed with Alagille syndrome (ALGS), alpha-1 antitrypsin (a-1AT) deficiency, bile acid synthesis and metabolism defects, and progressive familial intrahepatic cholestasis (PFIC) are enrolled. Siblings of participants with a-1AT deficiency who themselves have a-1AT deficiency of liver disease may also be enrolled.

Outcome

This study is ongoing.

Research Area

Digestive Diseases, Multidisciplinary Research, Endocrine Diseases and Metabolic Diseases, Liver Disease

Study Type

Observational

Study Sites

16

Study Start Date

2007-11

Study End Date

2029-05

Condition

Bile Duct Disorder, Progressive Familial Intrahepatic Cholestasis, Congenital Bile Acid Synthesis Defect, Alagille Syndrome, Cholestasis, Alpha 1-Antitrypsin Deficiency

Keywords

Pediatric End-Stage Liver Disease (PELD) score, Bone Mineral Density, Bile Acid Synthesis and Metabolism Defects, End-Stage Liver Disease (MELD) Score, Health-Related Quality of Life, Growth Failure, Pediatric Liver Diseases, Rare Genetic Disorders, Childhood Diseases

NIDDK Division

DDN

688
Participants

Target Population
Adults, Children, Transplant Patients
Ethnicity statistics is not available for this study
Location statistics is not available for this study

Public Documents Table
Document Name
Description
Document Type
File Format
Compliance
Download

Non-Public Documents (15)
Non-Public Documents Table
Document Name
Description
Document Type
File Format
Datasets (18)
Datasets Table
Dataset Name
Description
# of Records
# of Variables
File Format(s)
Specimens (73,989)
Specimens Table
Specimen
Count
BILE5
Bile Duct Tissue1
Bile-GB Aspirate21
Bile-GB Aspirate Tissue44
Cells670
DNA13176
EBV Transformed Cell Lines5330
Gallbladder84
Gallbladder Tissue94
Liver Biopsy220
Liver Perc Bx26
Liver Tissue1806
Liver Wedge Bx146
Lymph Node11
Lymph Node Tissue15
Lymphocytes537
Percutaneous Bx95
Plasma21656
SI/Colon Tissue136
Serum20082
Tissue112
Urine8574
Wedge Bx1142
Whole Blood6